IX Biopharma's (SGX:42C) net loss narrowed to SG$6.3 million for the half year ended Dec. 31, 2024, from SG$7.3 million a year earlier, a filing with the Singapore Exchange said on Friday.
Basic loss per share came in at SG$0.0072 from SG$0.0096 in the comparable period.
Revenue jumped 39% year over year to SG$3.7 million from SG$2.7 million, driven by stronger sales of medicinal cannabis products and services in Australia.